Zyversa Therapeutics Inc
ZVSA0.311USD
-0.238-43.30%
Market hours （ET）Quotes delayed by 15 min
799.48KMarket Cap
LossP/E TTM
More Details of Zyversa Therapeutics Inc Company
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Company Info
Ticker SymbolZVSA
Company nameZyversa Therapeutics Inc
IPO dateDec 21, 2021
CEOMr. Stephen C. (Steve) Glover
Number of employees7
Security typeOrdinary Share
Fiscal year-endDec 21
Address2200 N. Commerce Parkway
CityWESTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33326
Phone17542311688
Websitehttps://www.zyversa.com/
Ticker SymbolZVSA
IPO dateDec 21, 2021
CEOMr. Stephen C. (Steve) Glover
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
1.82K
--
Mr. Peter Wolfe
Mr. Peter Wolfe
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
127.00
--
Mr. Pablo A. Guzman, M.D.
Mr. Pablo A. Guzman, M.D.
Chief Medical Officer, Senior Vice President - Medical Affairs
Chief Medical Officer, Senior Vice President - Medical Affairs
76.00
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
--
--
Dr. Min Chul Park, Ph.D.
Dr. Min Chul Park, Ph.D.
Independent Director
Independent Director
--
--
Mr. James E. Sapirstein
Mr. James E. Sapirstein
Independent Director
Independent Director
--
--
Ms. Karen A. Cashmere
Ms. Karen A. Cashmere
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert G. (Rob) Finizio
Mr. Robert G. (Rob) Finizio
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
1.82K
--
Mr. Peter Wolfe
Mr. Peter Wolfe
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
127.00
--
Mr. Pablo A. Guzman, M.D.
Mr. Pablo A. Guzman, M.D.
Chief Medical Officer, Senior Vice President - Medical Affairs
Chief Medical Officer, Senior Vice President - Medical Affairs
76.00
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
--
--
Dr. Min Chul Park, Ph.D.
Dr. Min Chul Park, Ph.D.
Independent Director
Independent Director
--
--
Mr. James E. Sapirstein
Mr. James E. Sapirstein
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 28
Updated: Wed, May 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
5.85%
UBS Financial Services, Inc.
0.58%
Geode Capital Management, L.L.C.
0.45%
Virtu Americas LLC
0.36%
INCON Co., Ltd.
0.09%
Other
92.68%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
5.85%
UBS Financial Services, Inc.
0.58%
Geode Capital Management, L.L.C.
0.45%
Virtu Americas LLC
0.36%
INCON Co., Ltd.
0.09%
Other
92.68%
Shareholder Types
Shareholders
Proportion
Hedge Fund
5.89%
Investment Advisor
0.58%
Investment Advisor/Hedge Fund
0.45%
Research Firm
0.36%
Corporation
0.09%
Individual Investor
0.04%
Other
92.59%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
35
361.22K
7.41%
+216.61K
2025Q1
36
361.22K
7.45%
+216.32K
2024Q4
37
136.78K
7.85%
+71.47K
2024Q3
62
57.46K
5.12%
-24.65K
2024Q2
59
16.60K
1.67%
-51.32K
2024Q1
59
17.73K
1.94%
-42.02K
2023Q4
64
48.48K
46.23%
+4.78K
2023Q3
64
46.91K
75.21%
+1.88K
2023Q2
61
49.59K
86.96%
+14.63K
2023Q1
50
16.17K
61.42%
-21.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
285.04K
5.85%
+285.04K
--
Mar 31, 2025
UBS Financial Services, Inc.
28.33K
0.58%
+24.14K
+576.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
21.71K
0.45%
+13.81K
+175.00%
Mar 31, 2025
Virtu Americas LLC
17.53K
0.36%
-7.73K
-30.61%
Mar 31, 2025
INCON Co., Ltd.
4.28K
0.09%
--
--
Dec 31, 2023
Tower Research Capital LLC
2.15K
0.04%
-1.33K
-38.13%
Mar 31, 2025
Glover (Stephen C)
1.82K
0.04%
--
--
Apr 15, 2025
Wolfe (Peter)
127.00
0%
--
--
Apr 15, 2025
BofA Global Research (US)
111.00
0%
+2.00
+1.83%
Mar 31, 2025
Guzman (Pablo A)
76.00
0%
--
--
Apr 15, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Date
Type
Ratio
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
